 This phase III prospectively randomized study investigates whether chemoradiotherapy 45 Gy in 5 weeks with daily cisplatin and capecitabine after preoperative chemotherapy 3x ECC epirubicin, cisplatin, capecitabine and adequate D1 surgery leads to improved survival in comparison with postoperative chemotherapy 3x ECC. Furthermore, toxicity of both treatment regimens will be explored. 